Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Chase & Co (JPM) vs Nuwellis Inc (NUWE) Price & Performance

JPMorgan Chase & CoTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

JPMorgan Chase & Co vs Nuwellis Inc — how do they compare? JPMorgan Chase & Co trades at $362.07 (market cap $956.39B), while Nuwellis Inc trades at $1.5 (market cap $522.76K). The key difference: JPMorgan Chase & Co is far larger — about 1829501.1× Nuwellis Inc's market cap, and JPMorgan Chase & Co pays a 1.67% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.

JPMNUWE
Market Cap
$956.39B$522.76K
Volume
10,479,943
Sector
FinancialsTechnology
52-Week High
$362.04$220.50
52-Week Low
$282.84$1.42
Dividend Yield
1.67%
Enterprise Value
-$1.29M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Chase & Co

JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, near its pivot point of $359. The stock shows a bullish technical trend with moving averages supporting upside. Recent earnings beat expectations in Q1 and Q2 2026, with Q1 EPS of $5.94 versus $5.47 expected, though Q4 2025 missed. Revenue grew to $181.85B in 2025, and net income margin stands at 33.38%. A $1.50 dividend is scheduled for payment on July 31, 2026.

JPMorgan's outlook remains positive with analyst consensus at 'Moderate Buy' and a $374.18 price target, offering ~4% upside. Strong ROE of 18.43% and institutional accumulation highlight confidence. Risks include geopolitical tensions affecting oil markets and cybersecurity threats from AI, as noted in recent news. The stock's valuation at P/E 15.42 is reasonable relative to earnings growth potential.

Nuwellis Inc

NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.

The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Chase & Co

JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.

Read more on JPM

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE